"Paraganglioma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)
Descriptor ID |
D010235
|
MeSH Number(s) |
C04.557.465.625.650.700 C04.557.580.625.650.700
|
Concept/Terms |
Paraganglioma- Paraganglioma
- Paragangliomas
- Paraganglioma, Gangliocytic
- Gangliocytic Paraganglioma
- Gangliocytic Paragangliomas
- Paragangliomas, Gangliocytic
- Paragangliomas, Familial, 1
- Paragangliomata
- Paragangliomas 1
|
Below are MeSH descriptors whose meaning is more general than "Paraganglioma".
Below are MeSH descriptors whose meaning is more specific than "Paraganglioma".
This graph shows the total number of publications written about "Paraganglioma" by people in this website by year, and whether "Paraganglioma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1997 | 2 | 0 | 2 |
1999 | 0 | 2 | 2 |
2001 | 0 | 1 | 1 |
2004 | 1 | 1 | 2 |
2006 | 3 | 0 | 3 |
2007 | 2 | 2 | 4 |
2008 | 2 | 0 | 2 |
2009 | 1 | 0 | 1 |
2010 | 7 | 1 | 8 |
2011 | 1 | 0 | 1 |
2012 | 1 | 1 | 2 |
2013 | 4 | 1 | 5 |
2014 | 6 | 1 | 7 |
2015 | 3 | 0 | 3 |
2017 | 8 | 0 | 8 |
2018 | 6 | 0 | 6 |
2019 | 2 | 0 | 2 |
2020 | 7 | 0 | 7 |
2021 | 1 | 0 | 1 |
2022 | 3 | 0 | 3 |
2023 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paraganglioma" by people in Profiles.
-
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol. 2024 Mar; 20(3):168-184.
-
TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.
-
Succinate Dehydrogenase Mutations as Familial Pheochromocytoma Syndromes. Surg Oncol Clin N Am. 2023 04; 32(2):289-301.
-
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol. 2023 05; 11(5):345-361.
-
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med. 2023 Apr 01; 48(4):320-323.
-
Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med. 2023 May 01; 48(5):426-427.
-
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma. Endocr Relat Cancer. 2023 02 01; 30(2).
-
Commentary on "Clinical Characteristics and Surgical Outcomes of Carotid Body Tumors: Data from the Carotid Paraganglioma Cooperative International Registry (CAPACITY) Group". World J Surg. 2022 10; 46(10):2515-2516.
-
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 09 01; 29(9):533-544.
-
Heterogeneous Head and Neck Paraganglioma With Distinct Features on 123 I-MIBG and 68 Ga-DOTATATE Images. Clin Nucl Med. 2022 Sep 01; 47(9):813-814.